Literature DB >> 26351770

Improved sensitivity and specificity for prostate cancer diagnosis based on the urine PCA3/PSA ratio acquired by sequence‑specific RNA capture.

Kewen Zheng1, Yaling Dou2, Linfu He3, Hanzhong Li1, Zhicai Zhang3, Yu Chen2, Ali Ye2, Wenjing Liu2, Lingjun Kong2.   

Abstract

Prostate cancer antigen 3 (PCA3) is a non-coding RNA fragment that is overexpressed in prostate cancer cells. However, the clinical applications of PCA3 are highly limited due to the instability of RNA and the lack of reliable and efficient RNA extraction and purification methods. Thus, in the present study, we compared three different methods of RNA extraction to further confirm the higher yield of commercial magnetic beads with poly-T functionalization and a capturer strand. The current protocols for RNA extraction of i) the phenol-chloroform method, ii) the affinity column method and iii) magnetic beads with poly-T functionalization and a capturer strand were applied separately for RNA extraction in urine samples. Reverse transcription‑quantitative polymerase chain reaction was performed to evaluate the yield of the three methods of RNA extraction. Furthermore, 52 urine samples after prostate massage from patients suspected of a diagnosis of prostate cancer were collected. The Mag-Cap method and RT-PCR were applied to obtain the PCA3 score. The clinical value of the PCA3 score was investigated by comparison with the pathology of the prostate biopsy. The yield of the Mag-Cap method was higher than that of the phenolchloroform method and commercial kits. Thirty‑four patients were pathologically diagnosed with prostate cancer and 18 with benign prostatic hyperplasia (BPH). It was confirmed that the median PCA3 score was higher among the prostate cancer patients than those with benign disease (53.5 vs. 17, p=0.000). A sensitivity of 82.4% and a specificity of 77.8% were obtained when the cut-off value for the PCA3 score was 28.5. The Mag-Cap method was found to be more efficient for RNA extraction. The urinary PCA3 score is a promising method for prostate cancer screening, detection and diagnosis, and has the potential to reduce unnecessary prostate biopsies.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26351770     DOI: 10.3892/or.2015.4266

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  4 in total

1.  Diagnostic significance of urinary long non-coding PCA3 RNA in prostate cancer.

Authors:  Tao Wang; Xiangyun Qu; Jiajia Jiang; Peng Gao; Dingding Zhao; Xueqi Lian; Xiaohua Li
Journal:  Oncotarget       Date:  2017-04-20

2.  The long non-coding RNA PCA3: an update of its functions and clinical applications as a biomarker in prostate cancer.

Authors:  Ana Emília Goulart Lemos; Aline da Rocha Matos; Luciana Bueno Ferreira; Etel Rodrigues Pereira Gimba
Journal:  Oncotarget       Date:  2019-11-12

3.  Effect of upregulation of DD3 on early detection and prognosis in prostate cancer.

Authors:  Ke Wang; Huishan Zhao; Wenting Wang; Yingqian Zhu; Xuebao Zhang; Jiajia Ma; Haotian Tan; Yulian Zhang; Chunhua Lin
Journal:  Transl Androl Urol       Date:  2020-08

4.  Development of a highly sensitive digital PCR assay to quantify long non-coding RNA MYU in urine samples which exhibited great potential as an alternative diagnostic biomarker for prostate cancer.

Authors:  Di Liu; Huming Yin; Yong Wang; Yang Cao; Jian Yin; Jianping Zhang; Huancai Yin; Xiaojun Zhao
Journal:  Transl Androl Urol       Date:  2021-10
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.